Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis
- PMID: 38396063
- PMCID: PMC10891172
- DOI: 10.1038/s41598-024-54812-4
Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis
Abstract
We conducted a systematic search across medical databases, including PubMed, Web of Science, EMBASE, and Cochrane Library, up to March 2023. A total of 1944 subjects or individuals from 17 studies were included in our final analysis. The correlation coefficient (r) between sKlotho and calcium was [0.14, (0.02, 0.26)], and a moderate heterogeneity was observed (I2 = 66%, P < 0.05). The correlation coefficient (r) between Klotho and serum phosphate was [- 0.21, (- 0.37, - 0.04)], with apparent heterogeneity (I2 = 84%, P < 0.05). The correlation coefficient (r) between sKlotho and parathyroid hormone and vascular calcification was [- 0.23,(- 0.29, - 0.17); - 0.15, (- 0.23, - 0.08)], with no significant heterogeneity among the studies. (I2 = 40%, P < 0.05; I2 = 30%, P < 0.05). A significant correlation exists between low sKlotho levels and an increased risk of CKD-MBD in patients with CKD. According to the findings, sKlotho may play a role in alleviating CKD-MBD by lowering phosphorus and parathyroid hormone levels, regulating calcium levels, and suppressing vascular calcification. As analysis showed that sKlotho has an important impact on the pathogenesis and progression of CKD-MBD in CKD patients. Nonetheless, further comprehensive and high-quality studies are needed to validate our conclusions.
Keywords: Chronic kidney disease; Chronic kidney disease–mineral and bone disorder; Mineral metabolism; Soluble Klotho; Vascular calcification.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment.Nutrients. 2023 Mar 18;15(6):1470. doi: 10.3390/nu15061470. Nutrients. 2023. PMID: 36986200 Free PMC article.
-
Correlation Between Soluble Klotho and Vascular Calcification in Chronic Kidney Disease: A Meta-Analysis and Systematic Review.Front Physiol. 2021 Aug 13;12:711904. doi: 10.3389/fphys.2021.711904. eCollection 2021. Front Physiol. 2021. PMID: 34483963 Free PMC article.
-
Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows.Int J Mol Sci. 2024 Feb 3;25(3):1843. doi: 10.3390/ijms25031843. Int J Mol Sci. 2024. PMID: 38339121 Free PMC article. Review.
-
Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18. Bone. 2014. PMID: 24145307
-
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].Clin Calcium. 2015 May;25(5):645-53. Clin Calcium. 2015. PMID: 25926567 Review. Japanese.
References
-
- Drawz, P., et al. Chronic kidney disease. Ann. Intern. Med. 162(11), ITC1–16 (2015). - PubMed
-
- Glassock RJ, et al. The global burden of chronic kidney disease: Estimates, variability and pitfalls. Nat. Rev. Nephrol. 2017;13(2):104–114. - PubMed
-
- Ruiz-Ortega M, et al. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol. 2020;16(5):269–288. - PubMed
-
- Schwarz S, et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006;1(4):825–831. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials